Investigation of efficacy and safety of add-on therapy with DPP-4 inhibitor in type 2 diabetic patients poorly controlled with basal supported oral therapy
Not Applicable
- Conditions
- Type 2 diabetes
- Registration Number
- JPRN-UMIN000010849
- Lead Sponsor
- Department of Metabolism & Endocrinology Juntendo University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1)Patients with a history of hypersensitivity to vildagliptin 2)Patients with diabetic ketoacidosis, diabetic coma and type 1 diabetes 3)Patients with severe liver dysfunction 4)Patients with severe infection, perioperative and severe trauma 5)Patients with moderate renal dysfunction or endstage renal disease on hemodialysis 6)Patients with heart failure (NYHA/New York Heart Association stage 3 or severer) 7)Pituitary insufficiency or adrenal insufficiency 8)Patienst with diarrhea, vomiting, starvation and irregular food intake 9)Patients with proliferative diabetic retinopathy 10)Patients who are pregnant, lactating, and possibly pregnant women and those planning to become pregnant
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method